INCB059872 + azacitidine

**INCB059872 + azacitidine** is a combination therapy under clinical investigation for the treatment of acute myeloid leukemia (AML), particularly in newly diagnosed, treatment-naive patients who are unfit to tolerate standard intensive chemotherapy[3][7].\n- **INCB059872** is a small molecule, selective, irreversible inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A)[1][2][7]. LSD1 is an epigenetic modulator involved in chromatin remodeling and regulation of gene expression, especially impacting cell differentiation and proliferation; its inhibition can induce differentiation and growth arrest in myeloid malignancies[1][7].\n- **Azacitidine** is a nucleoside analog DNA methyltransferase inhibitor that induces DNA hypomethylation and direct toxicity to abnormal hematopoietic cells, resulting in apoptosis and differentiation.\n- The primary indication for the combination is AML (acute myeloid leukemia)[3][7], targeting poor-risk and treatment-related AML subpopulations; synergy is hypothesized by combining LSD1 inhibition with DNA hypomethylation[7].\n- Gene expression profiles in patient bone marrow have demonstrated that the combination can induce differentiation and modulate key lineage programs regulated by GFI1/GFI1B[7].

Other names

INCB059872 + AZA